Recently Featured

ARPA-H to Invest $62 Million in AI Development for Heart Failure Treatment

September 25, 2026
ARPA-H, the advanced research agency under the U.S. Department of Health and Human Services, has announced a substantial investment of $62.7 million aimed at developing artificial intelligence technologies to enhance the treatment of heart failure. This initiative, named ADVOCATE, seeks to create partially autonomous AI systems that will be authorized by the FDA to assist…

Increasing CHO Cell Productivity by Overexpressing Pabpc1 Gene

September 25, 2026
Researchers from BeOne Medicines (formerly BeiGene) have demonstrated that overexpressing the cytoplasmic poly(A)-binding protein gene Pabpc1 can enhance protein titers in Chinese hamster ovary (CHO) cell lines by 30–50%. This finding, detailed in a recent publication, shows consistent results across various antibody formats, including multispecific and monoclonal antibodies. This advancement opens avenues for biomanufacturers to…

Kura Spins Diabetes Work into a Lilly-Backed Biotech Startup

September 25, 2026
Kura Oncology has announced the establishment of Caspian Therapeutics, a new biotech startup focused on developing menin inhibitors for diabetes and other cardiometabolic conditions. This strategic move is backed by Eli Lilly, signaling a significant shift in Kura’s research focus from oncology to metabolic diseases. The transition to Caspian Therapeutics highlights the growing interest in…

FDA Approves Bayer’s Hyrnuo for First-Line Treatment of HER2-Mutant Lung Cancer, Intensifying Competition with Hernexeos

September 25, 2026
Bayer has secured FDA approval for its tyrosine kinase inhibitor, Hyrnuo, as a first-line treatment for patients with HER2-mutant non-small cell lung cancer. This milestone comes approximately six months after Boehringer Ingelheim received a similar endorsement for its competing TKI, Hernexeos. The approval of Hyrnuo marks a significant advancement in targeted therapies for this specific…

Ongoing Cases